Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation

CONTEXT High on-treatment platelet reactivity is associated with atherothrombotic events following coronary stent implantation. OBJECTIVE To evaluate the capability of multiple platelet function tests to predict clinical outcome. DESIGN, SETTING, AND PATIENTS Prospective, observational, single-cente...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2010-02, Vol.303 (8), p.754-762
Hauptverfasser: Breet, Nicoline J, van Werkum, Jochem W, Bouman, Heleen J, Kelder, Johannes C, Ruven, Henk J. T, Bal, Egbert T, Deneer, Vera H, Harmsze, Ankie M, van der Heyden, Jan A. S, Rensing, Benno J. W. M, Suttorp, Maarten J, Hackeng, Christian M, ten Berg, Jurriën M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:CONTEXT High on-treatment platelet reactivity is associated with atherothrombotic events following coronary stent implantation. OBJECTIVE To evaluate the capability of multiple platelet function tests to predict clinical outcome. DESIGN, SETTING, AND PATIENTS Prospective, observational, single-center cohort study of 1069 consecutive patients taking clopidogrel undergoing elective coronary stent implantation between December 2005 and December 2007. On-treatment platelet reactivity was measured in parallel by light transmittance aggregometry, VerifyNow P2Y12 and Plateletworks assays, and the IMPACT-R and the platelet function analysis system (PFA-100) (with the Dade PFA collagen/adenosine diphosphate [ADP] cartridge and Innovance PFA P2Y). Cut-off values for high on-treatment platelet reactivity were established by receiver operating characteristic curve analysis. MAIN OUTCOME MEASUREMENT The primary end point was defined as a composite of all-cause death, nonfatal acute myocardial infarction, stent thrombosis, and ischemic stroke. The primary safety end point included TIMI (Thrombolysis In Myocardial Infarction) criteria major and minor bleeding. RESULTS At 1-year follow-up, the primary end point occurred more frequently in patients with high on-treatment platelet reactivity when assessed by light transmittance aggregometry (11.7%; 95% confidence interval [CI], 8.9%-15.0% vs 6.0%; 95% CI, 4.2%-8.2%; P 
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2010.181